The cardiac marker testing market is expected to reach ~USD 3.50 Billion by 2021 from USD 2.30 Billion in 2016, at a CAGR of 8.8% between 2016 and 2021. Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for identification of novel cardiac biomarkers are propelling the growth of the global market. However, technical problems related to sample collection and storage and issues related to regulatory and reimburse systems are some of the major factors restraining the growth of this market.
On the basis of type, the global cardiac marker testing market is segmented into troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment comprises galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine. The troponin I and T segment is expected to grow at the highest CAGR owing to the high sensitivity and specificity, longer elevation time, and rapid prediction of outcomes or mortality.

On the basis of product, the global market has been divided into two segments, namely, reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. The reagents and kits segment is expected to grow at the highest CAGR during the forecast period. Increasing number of cardiac biomarker tests performed due to the growing aging population and burden of cardiovascular diseases, availability of various reagents and kits, and the continuous launch of new, faster, and reliable products is contributing to the high growth of this market segment.

The global cardiac marker testing technology market is segmented on the basis of type of testing into laboratory testing and point-of-care testing. The point-of-care testing segment is the fastest-growing segment in this market owing to the advantages offered by it (such as reductions in length of stay, improved emergency department efficiency, increased patient satisfaction and user experience, better turnaround times, and simpler sample collection method versus that in central lab testing), rising hospital point-of-care (POC) testing procedures, and technological advancements with regard to the development of advanced, faster, and easy-to-use devices.

Based on disease, the market is segmented into myocardial infarction and congestive heart failure. The myocardial infarction segment is expected to account for the largest share of the global cardiac marker testing market in 2016, and is expected to grow at the highest CAGR during the forecast period. The large share and high growth in this segment can be attributed to the increasing number of patients requiring investigation for diagnosis of acute myocardial infarction in emergency departments compared to other cardiac disorders.

North America is expected to account for the largest share of the global cardiac marker testing market in 2016, followed by Europe and Asia-Pacific. The Asia-Pacific market is expected to register the highest CAGR during the forecast period. The high growth in this segment can be attributed to rising prevalence and incidence of cardiovascular diseases, public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians, and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars in the region.

The cardiac marker testing market is highly competitive owing to the presence of a number of large and small firms. With improving industry standards, the global market has been witnessing several product innovations. New product launches was the key growth strategy adopted by market players to strengthen their market positions.